

# THE CHALLENGES OF PBM IMPLEMENTAION IN THE REAL WORLD

Aryeh Shander, MD, FCCM, FCCP, FASA

Emeritus Chief Department of Anesthesiology and Critical Care

Englewood Hospital and Medical Center, Englewood, New Jersey

Courtesy Clinical Professor UF College of Medicine

Adjunct Clinical Professor of Anesthesiology, Medicine and Surgery

Icahn School of Medicine at Mount Sinai, New York

Clinical Professor of Anesthesiology Rutgers Medical School, New Jersey

### OVERVIEW

- Defining change (PBM) and barriers to implementation
- The aim/goals of new programs
- What are the (REAL) barriers
- Are the implementation challenges generalizable?
  - Are all barriers to implementations the same?
- Can these barriers be overcome and If so, how?

#### Change comes from outside

There is nothing permanent except change *Heraclitus*, Greek philosopher, 500 BCE

A wise man adapts himself to circumstances, as water shapes itself to the vessel that contains it.

-Chinese Proverb

Implementation is how we react to it!

# DISRUPTION?

Only if someone notices

# How do we Work? The Status Quo

- We collect information from the past
- We incorporate it to the present, thinking it will shape the future
- Bound by the present that continues into the future no change
- Single direction undisturbed by change
- Change represents a new direction
- Disturbs the status-quo
- Why do things differently?

The difference in what is important and for whom? This is how we see the world - mostly from our vantage point

### The rest of medicine

PBM

# Unrelated examples do others struggle as we do?

#### Challenges in implementing antimicrobial stewardship (AMS) in organ transplant centers in India

Abdul Ghafur<sub>1</sub> Nitin Bansal<sub>2</sub>

#### "Real World Pressure"

- The Society for Healthcare Epidemiology of America (SHEA) defines *Anti-microbial Stewardship(AMS)* as "coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug regimen, dose, and duration of therapy and route of administration."
- The goal: Tackling antibiotic resistance Negative patient outcome
- > 2012, Chennai Declaration on antibiotic resistance AMR
  - The declaration was a call for a national policy and was intended to be a practical and achievable plan.

#### Challenges in implementing antimicrobial stewardship (AMS) in organ transplant centers in India

Abdul Ghafur<sub>1</sub> Nitin Bansal<sub>2</sub>

- The ask policy changes that will translate into clinical actions
  - Including no OTC antibiotics
  - Colistin restriction in poultry
- By 2017 terms used to describe progress:
  - Snail's pace
  - ► Still in primitive stage
  - Loss of momentum
- There were some large academic hospitals with excellent AMS

# Why Can't Change in Medicine be Accelerated or Should it?

Unintended consequences can be detrimental Insufficient conclusive data Controversies Resources

CULTURE! TRADITION!

#### **CORE Elements of Stewardship**

- Hospital leadership (Admin and Clinical) commitment
- Leadership accountability (Taking responsibility)
- Pharmacy/medication expertise Evidence Based AB use
- Action
- Tracking data collection -KPI
- Data analysis and reporting Department/individual performance
- Education

#### The Challenges – our mantra!

- Getting the needed response from leadership commitment
  - Cost of blood
  - ► Risks of blood
  - Risks of anemia
  - Limited benefits of blood transfusion
  - ► Understanding PBM
    - Treating a disease (the patient), not a number
    - > Improved clinical outcomes at lower resource utilization
    - Blood isn't plentiful, PBM takes the pressure off
    - Real world experience

DO we really know what they hear?

#### The Challenges

- > Leadership accountability
  - > WHO declaration on PBM
  - > Professional organizations approach to PBM
  - > Support those departments that join early

#### The Challenges

- > Expertise not easy to find
  - Identifying clinical champions
  - > Identifying outside resources
  - > Look at other established centers for expert help
  - > Sending champions to learn more

#### The Challenges

- Action identify the 'low lying fruit' where the first effort of PBM is implemented
- Data collection on blood use, adherence to PBM and other KPI
- Creating a timely 'report card' both for individuals and departments
- Aggressive education program

#### Patient Blood Management Bundles to Facilitate Implementation


Patrick Meybohm <sup>a,\*</sup>, Toby Richards <sup>b</sup>, James Isbister <sup>c</sup>, Axel Hofmann <sup>d</sup>, Aryeh Shander <sup>e</sup>, Lawrence Tim Goodnough <sup>f</sup>, Manuel Muñoz <sup>g</sup>, Hans Gombotz <sup>h</sup>, Christian Friedrich Weber <sup>a</sup>, Suma Choorapoikayil <sup>a</sup>, Donat R. Spahn <sup>i</sup>, Kai Zacharowski <sup>a</sup>

Despite the demonstrated benefits of PBM, many barriers limit translation of PBM guidelines into clinical practice worldwide, particularly due to lack of knowledge, lack of interdisciplinary commitment, lack of resources, and general concerns. Strategies for overcoming the hurdles often include the use of multimodal "care bundles" and specific designed measures according to local conditions. Therefore, the PBM "bundles" approach, which incorporates individual, low-threshold stepwise selection of the most feasible measures, depending on local cultural conditions, may serve as a new concept of "how to implement PBM."

Block 1: PBM Project Management
Involvement of Key PBM Stakeholders
Undergraduate and Postgraduate Education
Local Standard Operating Procedures/Protocols
Block 2: First Strategy—Manage Patient's Anemia
Preoperative Management of Anemia (Subgroup of Surgical Patients)
Optimizing Cardiovascular and Pulmonary Function to Improve Tolerance of Anemia
Management of Anemia in Hospitalized Patients and/or After Surgery
Block 3: Second Strategy—Optimizing Coagulopathy
Preoperative Management of Coagulopathy
Hemostasis Management in Hospitalized Patients
Block 4: Third Strategy—Interdisciplinary Blood Conservation Modalities
Reduction of Diagnostic-Associated Blood Loss
Reduction of Surgery-Related Blood Loss (Subgroup of Surgical Patients)
Block 5: Fourth Strategy—Optimal Blood Use With Patient-Centered Decision Making
Patient-Centered Decision Making
Block 6: PBM-Related Metrics, Patient's Outcome, Benchmark
Patient Blood Management-Related Metrics
Patient's Outcome
Benchmarking
Program Budget for PBM
Hospital Audit for PBM
Hospital Accreditation for PBM
•

Block 1: General PBM project management	
Involvement of key PBM stakeholders [role]	
PBM coordinator with protected time [central role for	0 🗆 1 🗆 2 🗀
communication, networking, education, documentation, and	
benchmarking]	0 - 1 - 2 -
Hospital board of directors (eg, chief medical officer, chief executive officer, chief nursing officer) [support; official directive]	0 🗆 1 🗆 2 🖂
Surgeons (eg, orthopedic/trauma, cardiac, vascular, visceral,	0 🗆 1 🗆 2 🗀
trauma, urology, neurosurgery) [interdisciplinary consensus]	
Anesthesiologists/intensive care specialists [central role for	0 🗆 1 🗆 2 🖂
perioperative care]	
Transfusion medicine specialists/transfusion committee	0 🗆 1 🗆 2 🖂
[prevention of blood wastage, optimal blood use, changes in	
donor blood management]	
Internists/gastroenterologists/hematologists/cardiologists/	0 🗆 1 🗆 2 🖂
nephrologists [anemia management, optimal blood use]	00100
General practitioners/family doctors [determine the necessity for	0 🗆 1 🗆 2 🗀
elective surgery, assign patients to a hospital, preoperative anemia management]	
Patient's representative [need to be informed about the different	0 🗆 1 🗆 2 🗀
alternatives to treat anemia/create awareness]	0 1 1 2 1
Pediatrics [mainly refers to blood conservation strategies]	0 🗆 1 🗆 2 🗀
Central laboratory/laboratory scientists [smaller blood	0   1   2
collecting tubes]	
Pharmacists/purchasing department [introduction of new	0 🗆 1 🗆 2 🔲
drugs for the management of anemia and coagulopathy]	
Information technology department [sampling of routine data	0 🗆 1 🗆 2 🗀
and key performance metrics]	00100
Finance department [finance experience for program budget	0 🗆 1 🗆 2 🗀
plan, initial project costs; hospital-wide cost savings] Quality management [project management experience; PBM	0 🗆 1 🗆 2 🗀
as a fixed part of a quality improvement initiative]	0 1 1 2 1
Public affairs [dissemination channels/marketing of the PBM	0 🗆 1 🗆 2 🗀
project (eg, via journals/Intranet/e-mails/posters/roll-ups/press	
conferences)]	
Undergraduate and postgraduate education	
Undergraduate education (nursing school/medical school)	0 🗆 1 🗆 2 🗀
Postgraduate education of physicians/clinicians (lectures,	0 🗆 1 🗆 2 🖂
workshops; initial and once a year)	004000
Postgraduate education of nurses (intensive care unit, normal	0 🗌 1 🗎 2 📗
ward; initial and once a year) Certificate (eg, by online E-learning courses)—to enhance PBM	0 🗆 1 🗆 2 🗀
education and knowledge transfer	
Local standard operating procedures/protocols	
Standard operating procedures for PBM	
Anemia management	0 🗆 1 🗆 2 🗀
Coagulation management	0   1   2
Blood conservation	0 🗆 1 🗆 2 🖂
Optimal blood use/transfusion of blood products (list of index	0 🗌 1 🔲 2 🔲
procedures for "type and screen" or "type and crossmatch (and	
supply)")	
Massive hemorrhage protocols (including such as damage	
controlled surgery, arterial embolization, hemotherapy algorithm)	001020
Massive hemorrhage (in general) Postpartum hemorrhage	0
Trauma associated hemorrhage	0   1   2
Cardiac surgery associated hemorrhage	0   1   2


#### **Surviving Sepsis Campaign**



CLINICAL

#### Surviving Sepsis Campaign Adult Guidelines


Review guidance for clinicians caring for adult patients with sepsis or septic shock.



**GUIDELINE** 

#### Surviving Sepsis Campaign Pediatric Guidelines

Review guidance for clinicians caring for pediatric patients with sepsis or septic shock.



CLINICAL

#### Surviving Sepsis Campaign COVID-19 Guidelines

Review guidelines on the management of critically ill adults with COVID-19.

### The Surviving Sepsis Campaign Bundle: 2018 Update

Mitchell M. Levy, MD, MCCM<sup>1</sup>; Laura E. Evans, MD, MSc, FCCM<sup>2</sup>; Andrew Rhodes, MBBS, FRCA, FRCP, FFICM, MD (res)<sup>3</sup>

CCM 2018

#### **ORIGINAL ARTICLE**

#### Epidemiology, Management, and Outcomes of Sepsis in ICUs among Countries of Differing National Wealth across Asia

Andrew Li<sup>1,2</sup>, Lowell Ling<sup>3</sup>, Hanyu Qin<sup>4</sup>, Yaseen M. Arabi<sup>5</sup>, Sheila Nainan Myatra<sup>6</sup>, Moritoki Egi<sup>7</sup>, Je Hyeong Kim<sup>8</sup>, Mohd Basri Mat Nor<sup>9</sup>, Do Ngoc Son<sup>10</sup>, Wen-Feng Fang<sup>11,12</sup>, Bambang Wahyuprajitno<sup>13</sup>, Madiha Hashmi<sup>14</sup>, Mohammad Omar Faruq<sup>15</sup>, Boonsong Patjanasoontom<sup>16</sup>, Maher Jaffer Al Bahrani<sup>17</sup>, Babu Raja Shrestha<sup>18</sup>, Ujma Shrestha<sup>18</sup>, Khalid Mahmood Khan Nafees<sup>19</sup>, Kyi Kyi Sann<sup>20</sup>, Jose Emmanuel M. Palo<sup>21</sup>, Naranpurev Mendsaikhan<sup>22</sup>, Aidos Konkayev<sup>23,24</sup>, Khamsay Detleuxay<sup>25</sup>, Yiong Huak Chan<sup>26</sup>, Bin Du<sup>4</sup>, Jigeeshu Vasishtha Divatia<sup>6</sup>, Younsuck Koh<sup>27</sup>, Charles D. Gomersall<sup>3</sup>, and Jason Phua<sup>1,28</sup>; on behalf of the MOSAICS II Study Group; for the Asian Critical Care Clinical Trials Group

	All (n = 4,980)	Low- to Lower- Middle-Income Countries/Regions (n = 1,561)	Upper- Middle-Income Countries/Regions (n = 1,890)	High-Income Countries/Regions (n = 1,529)	<i>P</i> Value
Completion of elements within 1 h, $n$ (%)* Antibiotics Blood cultures Lactate measurement Full bundle Completion of elements within 3 h, $n$ (%)* Antibiotics Blood cultures Lactate measurement Full bundle Time to completion, min, median (IQR)† Antibiotics Blood cultures	2,343 (47.0) 2,244 (45.1) 2,455 (49.3) 1,072 (21.5) 3,562 (71.5) 2,876 (57.8) 2,994 (60.1) 1,822 (36.6) 60 (30–150) 43 (15–148)	883 (56.6) 789 (50.5) 734 (47.0) 406 (26.0) 1,220 (78.2) 947 (60.7) 863 (55.3) 613 (39.3) 49 (25–110) 34 (15–104)	911 (48.2) 784 (41.5) 950 (50.3) 418 (22.1) 1,313 (69.5) 972 (51.4) 1,162 (61.5) 620 (32.8) 60 (25–158) 44 (15–203)	549 (35.9) 671 (43.9) 771 (50.4) 248 (16.2) 1,029 (67.3) 957 (62.6) 969 (63.4) 589 (38.5) 90 (37–180) 54 (19–152)	<0.001 <0.001 0.094 <0.001 <0.001 <0.001 0.001 <0.001 <0.001
	` ,	,	` ,	` ,	

system.

#### PBM is a concept, not one treatment

Multimodal Patient Blood Management Program Based on a Three-pillar Strategy

A Systematic Review and Meta-analysis

Friederike C. Althoff,\* Holger Neb, MD,\* Eva Herrmann, PhD,† Kevin M. Trentino,‡ Lee Vernich,§ Christoph Füllenbach, PhD,\* John Freedman, MD,¶ Jonathan H. Waters, MD,|| Shannon Farmer, MD,\*\*†† chael F. Leahy, MD,‡‡ Kai Zacharowski, MD, PhD,\* Patrick Meybohm, MD,\* and Suma Choorapoikayil, PhD\*



#### Number of units of allogeneic RBC per patient

		PBM	_		ol (pre-			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Orthopedic sur									
So-Osmann 2014		1.1	190	0.61	1.6	127	4.6%	-0.25 [-0.57, 0.07]	
Kopanidis 2016		2.04	100	2.05	1.1	100	3.4%	1.11 [0.66, 1.56]	
Freedman 2008		0.83	1127	0.51	1.04	1089		-0.17 [-0.25, -0.09]	
Ma 2014	0.24	0.83	33	0.81	1.28	37	3.1%	-0.57 [-1.07, -0.07]	
Theusinger 2014		1.25	6721	0.68	1.68	2150		-0.34 [-0.42, -0.26]	
Meybohm 2016		0.16	16298	1.46		12633		-0.22 [-0.22, -0.22]	
Leahy 2017 Subtotal (95% CI)	0.16	0.75	11942 <b>36411</b>	0.27	1.02	10304 <b>26440</b>		-0.11 [-0.13, -0.09] -0.18 [-0.26, -0.09]	
Heterogeneity: Tau <sup>2</sup> =	0.01: 0	Chi <sup>2</sup> =	125.65, d	f = 6 (P	< 0.000	$01$ ): $I^2 =$	95%		
Test for overall effect									
Cardiac surgery	7								
Freedman 2008		2.03	275	2.01	2.7	274	3.8%	-0.85 [-1.25, -0.45]	
Brevig 2009		1.82	479	1.43	3.08	530		-0.90 [-1.21, -0.59]	
Gross 2015		1.57	2275	1.28	2.34	387		-0.67 [-0.91, -0.43]	
Mevbohm 2016		0.46	7904	4.65	0.46	5630		-0.97 [-0.99, -0.95]	
Leahy 2017		2.15	1431	1.46	3.67	1096		-0.81 [-1.05, -0.57]	
Subtotal (95% CI)	0103		12364	21.10	2.07	7917		-0.87 [-1.00, -0.74]	
Heterogeneity: Tau² = Test for overall effect	: Z = 12				J.09); I	= 50%			
Vascular surger			200				27200		
Freedman 2008		3.82	232	2.12	4.39	287	2.0%	-0.37 [-1.08, 0.34]	
Meybohm 2016		0.52	5823	4.9	0.53	4377		-1.13 [-1.15, -1.11]	
Leahy 2017 Subtotal (95% CI)	0.38	1.51	1870 <b>7925</b>	0.77	2.43	1760 <b>6424</b>		-0.39 [-0.52, -0.26] - <b>0.66</b> [- <b>1.29</b> , - <b>0.04</b> ]	
Heterogeneity: Tau² = Test for overall effect				f = 2 (P	< 0.000	01); I <sup>2</sup> =	98%		
General surgery	V								
Meybohm 2016		0.16	13694	2.39	0.16	9164	6.9%	-0.30 [-0.30, -0.30]	
Leahy 2017	0.31	1.59	5437	0.49	2.17	4512	6.7%	-0.18 [-0.26, -0.10]	
Subtotal (95% CI)			19131			13676	13.6%	-0.25 [-0.36, -0.13]	•
Heterogeneity: Tau <sup>2</sup> =	= 0.01; (	Chi <sup>2</sup> =	9.52, df =	1 (P = 0	0.002); [	$^{2} = 89\%$			
Test for overall effect	Z = 4.	13 (P <	0.0001)						
Other fields									
Meybohm 2016	1.5	4.8	49856	1.7	5.6	36513		-0.20 [-0.27, -0.13]	
Subtotal (95% CI)			49856			36513	6.7%	-0.20 [-0.27, -0.13]	•
Heterogeneity: Not ap Test for overall effect			0.00001	)					
Total (95% CI)			125687			90970	100.0%	-0.43 [-0.54, -0.31]	•
Heterogeneity: Tau <sup>2</sup> =	0.05:4	Chi <sup>2</sup> =		df = 17	7 (P < 0				
Test for overall effect					,, , 0.	55001),	100/	*	-2 -1 0 1
Test for subgroup dif					< 0.00	001), I <sup>2</sup> :	= 95.5%		More RBC units in pre-PBM More RBC units in PBM

17 studies 235.779 patients

39% fewer were transfused


Shorter hospital stay

Fewer complications

**Increased survival** 

### Patient Blood Management: Improving Outcomes for Millions While Saving Billions. What Is Holding It Up?

Axel Hofmann, Dr rer medic, ME,\*† Aryeh Shander, MD,‡§||¶ Neil Blumberg, MD,# Jeffrey M. Hamdorf, MD, PhD,\* James P. Isbister, MB,\*\* and Irwin Gross, MD††



#### What about PBM?


Making patient blood management the new norm(al) as experienced by implementors in diverse countries

Axel Hofmann<sup>1,2†</sup>, Donat R. Spahn<sup>1†</sup>, Anke-Peggy Holtorf<sup>3,4\*†</sup> and PBM Implementation Group

Despite evidence that PBM improves patient outcome at lower costs "PBM is not yet adopted broadly"

Survey of PBM implementor across multiple countries: Asia, Latin America, Australia, Central and Eastern Europe, Middle East and Africa

#### What is (are) the main driver for PBM?



#### Rating Of Barriers

Barriers	Austral
Change of work practice	1.
Collaboration / communication	4.0
No / limited PBM experience	3.0
Process / Feasibility	3
Strong belief in transfusion	0
Number of staholders	1.
Cost	0
Sustainability	2.
'Competition' w. other interventions	0

Red 3 or higher White 2.01 – 2.99 Green 2 or lower Change of work practice

Collaboration / communication

No / limited PBM experience

Process / Feasibility

Strong belief in transfusion

Number of staholders

Cost

Sustainability

'Competition' w. other interventions

N = 35


udi Arabia	Sth Africa	Sth Korea	Switzerland	Turkey	Average	STDev
3.0	3.5	2.5	3.0	3.3	3.1	0.74
3.3	3.0	2.8	2.0	3.0	3.0	0.69
3.3	3.3	3.3	4.0	2.5	2.9	0.52
2.5	3.0	3.3	3.0	2.2	2.8	0.44
2.8	3.0	3.8	3.0	3.0	2.7	1.06
2.8	2.0	1.5	2.0	3.7	2.3	1.05
1.8	2.0	2.5	2.0	1.5	2.2	0.85
2.3	1.0	1.8	3.0	2.0	1.7	0.87
1.8	2.0	1.8	2.0	1.7	1.3	0.64


Overall: Change in work practice
Collaboration
Limited expertise
Feasibility
Strong belief in transfusion

#### **Accelerators and Inhibitors**

#### N=46

Accelerators and Inhibitors for Patient Blood Management





#### EXISTING PBM RELATED DOCUMENTS

- PBM Guidelines, National Blood Authority, Australia
- Supporting PBM in EU: A practical implementation guide for hospitals
- Standards for a Patient Blood Management Program (PBM Standards)
- SABM
- Blood utilization and PBM, Canada
- Organizations/societies on PBM:
  - SABM (Society of the Advancement of PBM), Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, KSPBM, ASPBM The International Foundation for PBM and more

### Impact of Implementing a Perioperative Patient Blood Management Program

#### INTERVENTION

Optimize Pre-Op Hemoglobin



Blood Sparing Techniques



Standardize Transfusion Protocols



#### **OUTCOMES**

Decrease Need for Transfusions



1.2 - 1.0

(avg. # of transfusions/patient)

No Increase in Post-Op Complications



6.4% - 6.2

(% patients w/ a complication)

Meybohm et al. Ann Surg. Aug 2016.



Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. Published by Lippincott Williams & Wilkins, Inc.

### Funded implementation


#### WESTERN AUSTRALIA PATIENT BLOOD MANAGEMENT PROGRAM

The Western Australian Patient Blood Management Program recently published the world's largest study on patient blood management outcomes. The study included over 600,000 patients admitted to Western Australia's four major adult hospitals between July 2008 and June 2014. Over the six-year study period, the program was associated with:


#### IMPROVED PATIENT OUTCOMES


mortality	infection	AMI/stroke	length of stay	
28%	21%	31%	15%	


#### IMPROVED KEY PROGRAM INDICATORS



#### REDUCTIONS IN UNITS OF BLOOD TRANSFUSED







#### PRODUCT COST SAVINGS

Over the six-year study period blood product cost savings were:

\$18.5M

#### **ACTIVITY BASED COST SAVINGS**

...however with the hospital costs of administering a transfusion added, the gross savings are estimated to be between:

\$80M-\$100M

#### Improving Patient Blood Management Programs: An Implementation Science Approach

Sherri Ozawa, MSN,\*†‡ Joshua Ozawa-Morriello, BSN,§ Seth Perelman, MD,|| Elora Thorpe, MSN,\* Rebecca Rock, RN,¶ and Bronwyn L. Pearse, PhD#\*\*

STEP 1: BUILD/IMPROVE PBM INSTITUTIONAL GOVERNANCE STRUCTURE, IDENTIFY GOALS, AND NEED FOR CHANGE

STEP 2: ADAPTING THE EVIDENCE AND GUIDELINE RECOMMENDATIONS TO THE LOCAL DEPARTMENT/INSTITUTION

STEP 3: IDENTIFYING AND OVERCOMING BARRIERS TO IMPLEMENTING PBM

**STEP 4: IMPLEMENTING THE CHANGE** 

STEP 5: MONITORING THE IMPLEMENTATION PROCESS

**STEP 6: EVALUATING OUTCOMES** 

STEP 7: SUSTAINING

Governance but cannot be "top heavy"

**Identify champions and stakeholders** 

Barriers can be social, cultural, environmental or organizational

A phased approach

Any measure of progress – knowledge to skill

Any reporting mechanism on clinical and financial data

Embedding a culture and "hardwiring" it

A&A 2023

### ONTraC: A 20-Year History of a Successfully Coordinated Provincewide Patient Blood Management Program: Lessons Learned and Goals Achieved

Katerina Pavenski, MD.\*†

Alanna Howell. RN.\*§ C. David Mazer. MD.II¶#


Gregory M. T. Hare, MI

Percent of Paitents with Infection

25 Locations; 1

8

Funded implementation




### Implementation of a comprehensive patient blood management program for hospitalized patients at a large United States medical center

Matthew A. Warner, MD<sup>1,2</sup>, Phillip J. Schulte, PhD<sup>3</sup>, Andrew C. Hanson, MS<sup>3</sup>, Nageswar R. Madde, MS<sup>2</sup>, Jennifer M. Burt, RN<sup>2</sup>, Andrew A. Higgins, RN<sup>2</sup>, Nicole M. Andrijasevic, RRT<sup>4</sup>, Justin D. Kreuter, MD<sup>5</sup>, Eapen K. Jacob, MD<sup>5</sup>, James R. Stubbs, MD<sup>5</sup>, Daryl J. Kor, MD<sup>1,2</sup>

<sup>1</sup>Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN

### Supported implementation

2010-2017 N - 400,998 Decrease LOS Decrease AE Over \$7M saved



#### Implementation Recommendations

- 1. Understand your institution's culture
- 2. Get leadership endorsement and participation
  - 1. Administrators, physicians and nurses
  - 2. Identify leaders as "champions"
  - 3. Seek reasonable resources
- 3. Start small one service line
- 4. Collect data early
- 5. Construct an educational program that also raises awareness
  - 1. Addresses each service line's concerns
  - 2. Specific scenarios
- 6. Feedback via collected data to show progress

### Helpful tools



POLICY BRIEF

THE URGENT NEED TO IMPLEMENT PATIENT BLOOD MANAGEMENT

WHO 2021



Guidance on implementing patient blood management to improve global blood health status





### Change Delayed is Change Denied: The Challenge of Patient Blood Management Implementation

Irwin Gross, MD,<sup>1</sup> Linda Shore-Lesserson, MD,<sup>2</sup> and Shannon L. Farmer, DHSc<sup>1,3</sup>

⁄ide

## From implementation to "hard wiring" The challenge of sustaining the change!

# When does implementation morph to ADOPTION? Are they the same?

# Changes in Practices After Implementation of a Patient Blood Management Program in French Surgical Departments: The National Multicenter Observational PERIOPES Study

Sigismond Lasocki, MD, PhD,\* Anissa Belbachir, MD,† Paul-Michel Mertes, MD, PhD,‡ Eric Le Pelley, MD,§ Laetitia Bosch, MD,|| Clémence Bezault, MD,¶ Samia Belarbia, DVM,# and Xavier Capdevila, MD, PhD\*\*

Increased anemia
detection/management
HLOS – decreased
Transfusion – decreased
Only in "mature" program

Still "too many patients with Preoperative anemia remained untreated

**RESULTS.**A total of 1618 patients (ASA physical status III and IV, 38% in the first period and 45% in the second period) were included in expert (N = 454) or pilot (N = 1164) centers during the first period (January 2017–August 2022) and 1542 (N = 440 and N = 1102, respectively) during the second period (January 2020–February 2023). After implementation of the PBM program, the rate of preoperative anemia treatment increased (odds ratio, 2.37; 95% confidence interval [CI], 1.20-4.74; P = .0136) and length of hospital stay in days decreased (estimate, -0.11; 95% CI, -0.21 to -0.02; P = .0186). Transfusion rate significantly decreased only in expert centers (odds ratio, 0.17; 95% CI, 0.03-0.88; P = .0354).

**CONCLUSIONS.**PBM practices in various surgical specialties improved significantly after the implementation of a PBM program. However, too many patients with preoperative anemia remained untreated. (Anesth Analg 2025;140:453–64)

### SUMMARY

- Defining change (PBM) and barriers to implementation
- The aim/goals of new programs
- What are the barriers
- Are the implementation challenges generalizable?
- Can these barriers be overcome, when and how?

#### CONCLUSION

- Change in medicine is an evolution, not a revolution and never complete
- Getting rid of the "old" vs. changing it, will confirm adoption
- Lagging adoption in an "implemented" institution is normal but frustrating – No one emphasizes that implementing is a long road uphill with many bumps
- Arm yourself with patience and resilience!
- Never give up, never surrender!



### THANK YOU

